| Half-life | 7 hours |
| Tmax | 1 h |
| Bioavailability | 99 % (approx) |
| Protein Binding | 30 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | High oral bioavailability ~100% → oral dose ≈ IV dose. Adjust in renal impairment. |
Severity: Severe
Adverse Effects:
Tendonitis, QT prolongation, dysglycemia, CNS effects
Contraindications:
Children, pregnancy (relative), history of tendon rupture with quinolones
Precautions:
Avoid ECG QT drugs combination; caution in diabetics due to dysglycemia risk